Genoway Stock

Genoway ROCE

The Return on Capital Employed (ROCE) of Genoway (ALGEN.PA) as of Sep 6, 2026 is 2.68 %. In the previous year, Return on Capital Employed (ROCE) was 9.76 % — a change of -72.53% (lower).

ROCE

2.68 %

YoY

-72.53%

Last updated:

In 2026, Genoway's return on capital employed (ROCE) was 2.68 %, a -72.53% increase from the 9.76 % ROCE in the previous year.

The Genoway ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
7.35 EUR
Jan 1, 2019
-10.66 EUR
Jan 1, 2020
-43.91 EUR
Jan 1, 2021
-31.56 EUR
Jan 1, 2022
5.88 EUR
Jan 1, 2023
11.88 EUR
Jan 1, 2024
9.76 EUR
Jan 1, 2025
2.68 EUR
The Genoway ROCE history
YEARROCEYoY
2.68 %-72.53%
9.76 %-17.89%
11.88 %+102.22%
5.88 %-118.61%
-31.56 %-28.12%
-43.91 %+312.09%
-10.66 %-245.01%
7.35 %-29.90%
10.48 %-20.32%
13.16 %+61.24%
8.16 %+66.87%
4.89 %—
Access this data via the Eulerpool API
Get Free API Key

Genoway Stock analysis

What does Genoway do? Genoway SA is a biotechnology company based in Lyon, France. It was founded in 2002 by Pierre Cadinot. The company specializes in the production of genetically modified mice for disease research and the development of new therapies. The business model of Genoway is to provide customers with customized genetically modified mice. The company offers a wide range of services, from consulting during the design phase to the delivery of modified mice. The company also offers services in the field of cell culture and transgene expression. Genoway is divided into different divisions to meet specific customer needs. For example, there is the "Knockout Mice" division, which specializes in producing mice that lack a specific target gene. These mice are used to study the function of the missing gene in vivo. Another area of Genoway is the production of "humanized mouse models". These are mice in which human genes have been inserted to model specific human diseases or to test the efficacy of drugs. These humanized mice are an important part of drug research in the pharmaceutical industry. Genoway also offers services in the field of inducible expression. This involves triggering the expression of a target gene in vivo to study the effects of the protein. This technology is particularly useful in the research of diseases such as cancer, where certain genes are only active in specific cells. In addition to these specialized services, Genoway also offers a wide range of standard services, such as the creation of stable cell lines or transgene expression in various organs and tissues. Genoway is a leading company in the development of genetically modified models for the study of human diseases. The company works closely with its customers to develop customized solutions that meet the specific requirements of each project. With its divisions and services, it aims to support its customers in the development of new therapies and drugs. Genoway is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Genoway's Return on Capital Employed (ROCE)

Genoway's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Genoway's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Genoway's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Genoway’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Genoway stock

Return on Capital Employed (ROCE) of Genoway is 2.68 % in 2026.

Return on Capital Employed (ROCE) of Genoway changed from 9.76 % to 2.68 %, representing a -72.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Genoway since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Genoway with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API
Get Free API Key

Profitability — Genoway

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Genoway